Previous 10 | Next 10 |
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to vutrisiran, an investigational therapeutic for the treatment of the polyneuropathy of hereditary transt...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 19 th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 8:40 am ET via webcast. A live audio webcast of t...
– RNAi Represents One of the Most Promising and Rapidly Advancing Frontiers in Biology and Drug Development Today with Potential to Transform Lives of Patients – – Blackstone Provides a Customized Investment at Scale to Enable Alnylam to Achieve Self-sustainable Fi...
Deploying some of its $150B cash hoard, Blackstone Group (NYSE: BX ) will invest $2B in Alnylam Pharmaceuticals (NASDAQ: ALNY ) aimed at boosting its pace of bringing products to market. More news on: The Blackstone Group Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stock...
Alnylam Pharmaceuticals (NASDAQ: ALNY) and Vir Biotechnology (NASDAQ: VIR) show no signs of slowing despite the current economic climate. These well-capitalized biotechs have ambitious plans to develop an array of innovative medicines. The companies recently banded together to ...
Biotech has held up surprisingly well in this market downturn, more or less tracking the S&P, but Alnylam ( ALNY ) has managed to outperform on a relative basis – showing only a small year-to-date decline. I’d like to believe that’s a recognition of the companyȁ...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed the rolling submission of its U.S. marketing application seeking approval of lumasiran, a glycolate oxidase-targeting RNAi therapeutic, for primary hyperoxaluria type 1 (PH1), a rare disorder caused by the buildup of oxalate in the ki...
− Lumasiran is the First Potential Therapeutic to Demonstrate Substantial Reduction in Urinary Oxalate Excretion – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the completion of the rolling submission of a New Dru...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) will collaborate with Dicerna Pharmaceuticals (NASDAQ: DRNA ) to investigate RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease , a relatively rare inherited disorder caused by the abnormally low productio...
- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam Retains Post-Phase 3 Opt-in Right for Ex-U.S. Commercialization - - Companies Complet...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...